Literature DB >> 28130929

Use of antenatal corticosteroids in special circumstances: a comprehensive review.

Everett F Magann1, Kjell Haram2, Songthip Ounpraseuth1, Jan H Mortensen2, Horace J Spencer2, John C Morrison3.   

Abstract

The aim of this study was to determine, in pregnancies complicated by preterm premature rupture of membranes (PPROM), hypertension, intrauterine growth restriction, multi-fetal gestations and pregnancies 23-26 weeks and ≥34 weeks' gestation, whether antenatal corticosteroids benefit the fetus. Literature review using PubMed, Web of Science, Clinical trials.gov, Cochrane Database of Systematic Reviews (1990-2015). Search terms linked special circumstances with corticosteroids. Randomized clinical trials, retrospective and prospective cohort studies, and case control studies were reviewed. In all, 468 abstracts were identified and 84 added from selected article bibliographies; of these, 503 abstracts were excluded, leaving 49 articles as the basis of review. The literature supports corticosteroids for PPROM up to 32-34 weeks without chorioamnionitis. Antenatal corticosteroids are beneficial for preterm infants of women with HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome/severe preeclampsia. Postpartum corticosteroid treatment of HELLP patients results in more rapid correction of liver enzymes, platelet counts, and urinary output, which can reduce maternal morbidity. Corticosteroids in twin pregnancies decrease respiratory distress syndrome but the effect is less than in singleton pregnancies. Corticosteroid effects on intrauterine growth restriction pregnancies are conflicting and steroid use should be individualized. Corticosteroid use for 23-26 weeks reduces neonatal mortality but not morbidity. In pregnancies of 34 weeks to 366/7  weeks, corticosteroids reduce respiratory distress syndrome, but follow-up studies are unavailable. No long-term adverse child developmental effects have been observed with one or two courses of corticosteroids, but three or more steroid courses lowers birthweight and organ weight, and there may be an increase in neurodevelopmental abnormalities. Longer follow up of corticosteroid-treated fetuses is required.
© 2017 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Keywords:  Corticosteroids; PPROM; growth restriction; hypertension; preeclampsia; respiratory distress syndrome; twins

Mesh:

Substances:

Year:  2017        PMID: 28130929     DOI: 10.1111/aogs.13104

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  3 in total

Review 1.  Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease.

Authors:  Sara Jarmakiewicz-Czaja; Aneta Sokal; Piotr Pardak; Rafał Filip
Journal:  Can J Gastroenterol Hepatol       Date:  2022-05-11

2.  Expectant Management of PPROM Improves Neonatal Outcome-A Retrospective Study of 562 Patients.

Authors:  Roxana Elena Bohilțea; Ana Maria Cioca; Vlad Dima; Ioniță Ducu; Corina Grigoriu; Valentin Varlas; Florentina Furtunescu
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

3.  Antenatal corticosteroids and preterm offspring outcomes in hypertensive disorders of pregnancy: A Japanese cohort study.

Authors:  Takafumi Ushida; Tomomi Kotani; Masahiro Hayakawa; Akihiro Hirakawa; Ryo Sadachi; Noriyuki Nakamura; Yoshinori Moriyama; Kenji Imai; Tomoko Nakano-Kobayashi; Fumitaka Kikkawa
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.